George W Sledge Jr. MD

Professor of Medicine, Indiana University

300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Fax+1 650-498-5840

Dr. Sledge is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sledge's full profile Already have an account?

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1981 - 1983
SSM Health/Saint Louis University School of MedicineResidency, Internal Medicine, 1977 - 1980
Tulane University School of MedicineClass of 1977

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2013 - 2028
IN State Medical License 1983 - 2013
LA State Medical License 1977 - 1983
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017

Clinical Trials

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2
COMPLETED
PHASE2
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer Start of enrollment: 2003 Jun 06
COMPLETED
PHASE3
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer
TERMINATED

Publications & Presentations

PubMed

1 citations
Development of indole derived non-orthosteric inhibitors for Proto-oncogene serine/threonine-protein kinase PIM-1.
Benedikt W Grau, Dhanir Tailor, Mallesh Pandrala, Katherine J Schultz, En-Chi Hsu
European Journal of Medicinal Chemistry. 2026-10-15
Differential impact of tumor-derived ESR1 mutations on elacestrant benefit in metastatic breast cancer.
George W Sledge, Joanne Xiu, Suzanne Fuqua, Jennifer R Ribeiro, Heather McArthur
Clinical Cancer Research. 2026-10-13
1 citations
Development and Validation of a Multimodal-Multitask Deep Learning Approach for Estimating Late Distant Recurrence Risk in HR-Positive Early Breast Cancer.
Eleftherios P Mamounas, Ming Chen, Joseph A Sparano, Md Ashequr Rahman, Yating Cheng
Cancer Research Communications. 2026-07-01

Lectures

The 15th International Symposium on Anti-Angiogenic Therapy: Recent Advances and Future Directions in Basic and Clinical Care Research
The University of Texas, M. D. Anderson Cancer Center, San Diego, California - 1/31/2013

Press Mentions

New Cancer Drugs Are Revolutionary. Why Don’t More Patients Get Them?September 30th, 2026
New AI Model Outperforms Oncotype DX for Predicting Recurrence Risk in Breast CancerSeptember 24th, 2026
Tailoring Treatment: Real-World Evidence Guides ADC Sequencing in Breast CancerSeptember 18th, 2025